指南与共识皮肤肿瘤

2022年NICE黑色素瘤评估与管理指南更新摘要

Melanoma: assessment and management summary of the 2022 update of the National Institute for Health and Care Excellence guidelines.
指南 / 共识 · Br J Dermatol · 2025-01-01

本文总结了英国国家卫生与临床优化研究所(NICE)2022年黑色素瘤指南更新的核心内容。更新反映了系统性治疗进步和手术策略演变,包括前哨淋巴结活检在分期中的明确作用、晚期疾病手术降级以及区域治疗对转运转移的拓展。这些进展改善了患者结局,但也增加了管理复杂性。

要点

  • 前哨淋巴结活检在分期和区域淋巴结管理中的作用已明确,减少了不必要的淋巴结清扫。
  • 晚期黑色素瘤有效系统治疗的出现允许手术降级,改变了局部治疗的作用和顺序。
  • 区域治疗对转运转移疾病有效,应作为多学科诊疗的一部分。

核心结论

  • NICE 2022年更新反映了黑色素瘤管理范式的转变,有效系统治疗和手术策略演变改善了临床结局。

研究设计与样本

  • 指南类文件:英国国家卫生与临床优化研究所(NICE)制定,由英国专家小组总结2022年更新内容。

主要发现

  • 黑色素瘤是英国第五常见癌症,占所有新发癌症的4%,预测2014至2035年发病率增加7%。
  • 自2015年NICE指南首次发布以来,有效系统治疗的引入使疾病管理发生范式转变。
  • 前哨淋巴结活检在分期和区域淋巴结管理中的作用变得清晰,减少了病理性淋巴结清扫的需求和指征。
  • 晚期疾病中有效治疗允许手术降级,改变了局部治疗的作用和顺序。
  • 针对转运转移的区域治疗已扩展,作为多学科诊疗的一部分可有效控制该模式疾病。

关键数值与推荐

  • 前哨淋巴结活检用于分期和区域淋巴结管理,减少不必要的淋巴结清扫。
  • 晚期疾病中有效系统治疗允许手术降级,调整局部治疗的作用和顺序。
  • 区域治疗用于转运转移疾病,作为多学科诊疗的一部分。

临床怎么用

  • 临床应依据NICE 2022更新,合理应用前哨淋巴结活检进行分期并减少不必要的淋巴结清扫。
  • 晚期黑色素瘤可考虑手术降级,结合有效系统治疗调整局部治疗顺序。
  • 转运转移疾病可采用区域治疗,并纳入多学科诊疗框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Melanoma is the fifth most common cancer in the UK, accounting for 4% of all new cases of cancer, with a predicted 7% increase in incidence between 2014 and 2035. In parallel, since the initial publication of the National Institute for Health and Care Excellence (NICE) melanoma guidelines in 2015, there has been a paradigm shift in the management of the disease, with the introduction of effective systemic therapies. These innovations have reshaped the management of melanoma throughout the patient journey, and improved clinical outcomes. Surgical management has evolved, with the role of sentinel node biopsy in staging and management of regional lymph nodes becoming clearly defined, and a reduction in the need and indications for morbid block dissections. In advanced disease, effective therapies have allowed a de-escalation of surgery, changing the role and sequencing of local therapies. Regional therapies for in-transit disease have expanded and are effective in controlling this pattern of disease as part of multidisciplinary care. These advances have undoubtedly improved the care for people with melanoma, but they have also increased the complexity of management. In this context, this article seeks to summarize the most relevant of the recent updates to the NICE guidelines. Melanoma is a common skin cancer in the UK. There are over 17,000 new cases diagnosed every year, which makes it the fifth most common cancer. There have been recent developments in the treatment available for people with melanoma. One example is drugs that help the patient’s immune system to fight melanoma cancer. At the same time, surgical techniques have evolved. These new therapies mean that some patients will need less extensive operations. This is especially important in the lymph node area. These developments are improving care for people with melanoma. Yet, there are other complexities and considerations needed when deciding treatment. As a result, it was necessary to revise the current clinical guidelines. In 2022 the National Institute for Health and Care Excellence (NICE) updated its recommendations. In the current study, a group of experts in the UK summarize the most recent updates in the NICE guidelines.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Smith MJ, Peach H, Keohane S, et al. Melanoma: assessment and management summary of the 2022 update of the National Institute for Health and Care Excellence guidelines. Br J Dermatol. 2025. PMID: 39836183. doi:10.1093/bjd/ljaf016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。